Compare stocks

INDP vs TECX

Indaptus Therapeutics, Inc. Common Stock and Tectonic Therapeutic, Inc. Common Stock

Compare the businesses

Indaptus Therapeutics, Inc. Common Stock

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate consists of Decoy20, which is used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, as well as for the treatment of advanced solid tumors. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Open INDP dashboard ↗

Tectonic Therapeutic, Inc. Common Stock

Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein-coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.

Open TECX dashboard ↗

Sign in to keep comparing stocks

You've viewed 3 distinct stock or comparison pages today. Sign in for 10 views per day.

3 of 3 daily views used. Your allowance resets at midnight Eastern time. Refreshes and chart changes do not use another view.

New to NexusTrade? Create a free account.

Choose another comparison ↗